SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

AVITA Medical, Inc. (RCEL) News

Follow AVITA Medical, Inc. (RCEL) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol RCEL Asset equity Sector Markets 90 days 5 Last 15.565 Updated Nov 06, 2026, 02:06 PM UTC Open live news feed Open RCEL chart & news
M AVITA Medical Reports Q3 Revenue Growth, Raises 2026 Guidance AVITA Medical reported third-quarter revenue of $26.1 million, up 53% year over year and 20% sequentially. It raised full-year revenue guidance to $92 million-$94 million from $86 million-$89 million and reaffirmed its Q EQUITY | Nov 06, 2026, 02:06 PM UTC H AVITA Medical Q2 2026 Earnings Call Transcript On Thursday, AVITA Medical (NASDAQ: RCEL ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and financ LIVE | Oct 12, 2026, 09:37 AM UTC L AVITA Medical management to participate in two investor conferences AVITA Medical said senior management will participate in the Lake Street Best Ideas Growth Conference and the Morgan Stanley Healthcare Conference. EQUITY | Sep 02, 2026, 08:17 PM UTC L RCEL - AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference RCEL - AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference EQUITY | Sep 02, 2026, 08:10 PM UTC L Lake Street raises Avita Medical price target to $12 Lake Street raised Avita Medical’s price target to $12.00 per share from $8.00. EQUITY | Aug 28, 2026, 03:28 PM UTC L BTIG raises RCEL price target to $11, keeps Buy BTIG raises its price target on RCEL to $11 from $7 and maintains a Buy rating. EQUITY | Aug 19, 2026, 12:17 PM UTC L AVITA Medical reports PermeaDerm study results with 70% economic advantage AVITA Medical says its PermeaDerm study demonstrates a 70% economic advantage versus allograft and reports comparable clinical outcomes. EQUITY | Aug 18, 2026, 11:45 AM UTC L AVITA Medical Raises FY2026 Sales Guidance from $80.000M-$85.000M to $86.000M-$89.000M vs $82.350M Est AVITA Medical (NASDAQ: RCEL ) raises FY2026 sales outlook from $80.000 million-$85.000 million to $86.000 million-$89.000 million vs $82.350 million estimate. EARNINGS | Aug 06, 2026, 08:10 PM UTC L RCEL - AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven - Click Fo RCEL - AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven EARNINGS | Aug 06, 2026, 08:02 PM UTC H Why ServiceNow Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket Shares of ServiceNow Inc (NYSE: NOW ) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results. ServiceNow reported quarterly earnings of 90 cents per share, whi EARNINGS | Jul 23, 2026, 08:35 AM UTC